CNBC's Meg Tirrell looks at some pharma and biotech stocks that are making news today. » Read More
Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.
It has been over a month and a half since the US House of Representatives passed its version of health care reform and today, the Senate passed its bill. Now the two bills must be reconciled and the debate will continue to heat up. Here are the biggest S&P Health Care gainers and losers over the past 6 months.
Our whales aren’t massive sea creatures, so much as massive investors who are massively wealthy... and they’ve recently surfaced to reveal their top holdings.
This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate. The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess. Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.
Stocks retreated Tuesday after several earnings reports beat expectations but economic numbers missed their targets. The Dow shed more than 50 points, or 0.5 percent, but still held above 10,000. The S&P and Nasdaq each lost about 0.6 percent.
Stocks retreated Tuesday after several earnings reports beat expectations but economic numbers missed their targets. Apple and Caterpillar surged after their earnings blew past forecasts.
Futures were poised for a modestly higher open on the strength of more earnings surprises from some of Wall Street's leading companies.
Following are the day’s biggest winners and losers. Find out why shares of Nike and Huntington Bancshares popped while Biogen and Saks dropped.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
With new data showing that consumers are unlikely to help spark growth anytime soon, can the market sustain its recent gains?
Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months. Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.
Stocks continued to struggle on Friday. Could this be the beginning of a real market correction? Mike Rubino, president of Rubino Financial, and Paul Schatz, president of Heritage Capital, discussed how investors should position their portfolios for the end of the third quarter.
Big money managers can instill confidence in individual stocks and you may be able to profit off their moves. Karen Finerman breaks down the holdings of the major money managers.
Opposition to the Obama administration's health care plan had a new voice Monday, as the U.S. Chamber of Commerce launched a critical ad campaign suggesting alternatives. But John Sullivan of Leerink Swann says this is a great time to buy health stocks.
A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?
Carl Icahn and all of the Elanians should be happy. Biogen Idec today reported encouraging trends regarding its all-important multiple sclerosis drug Tysabri.
Brent Wilsey, president of Wilsey Asset Management, and Rod Smyth, chief investment strategist of Riverfront Investment, shared their economic outlooks and advised investors how to seek maximum profits.
Investors are placing their bets ahead of a string of pharma earnings due both this week and next. What must you know?
Earnings season should provide a fresh view of the U.S. economy and may shake the stock market out of its summer doldrums.
Douglas Roberts, founder and chief investment strategist at ChannelCapitalResearch.com and Mike Williams, founder and managing partner at Genesis Asset Management shared their opposing market views and advised investors on where they should put their money.